Niraparib (Zejula, GlaxoSmithKline) is indicated 'as a monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy'.
The dosage schedule is available in the summary of product characteristics for niraparib.
The list price of niraparib is £4,500 for a 56‑pack of 100‑mg tablets, and £6,750 for an 84‑pack of 100‑mg tablets (BNF online, accessed November 2025).
The company has a commercial arrangement. This makes niraparib available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, GlaxoSmithKline did not disclose its Carbon Reduction Plan for UK carbon emissions.